However, the combination of EGFR inhibitors with cisplatin or radiotherapy shows improved response compared to monotherapy with erlotinib or cetuximab, raising the possibility that resistance of tumors to EGFR inhibitor monotherapy could be related to the functional heterogeneity of CSCs in advanced HNSCC [170, 173]. Here, EGFR is linked to head and neck squamous cell carcinoma.